|
Tuesday, March 28, 2023 |
|
OrbusNeich Plans to Set up Its Largest R&D and Production Base in Fuchun Bay New Town, Hangzhou, the PRC |
OrbusNeich Medical (Zhejiang) Company Limited ("OrbusNeich Zhejiang"), a wholly-owned subsidiary of OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specialized in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures more info >> |
|
Wednesday, March 8, 2023 |
|
业聚医疗公布上市后首份全年业绩,收入创新高达1.37亿美元,经调整净利润升25%至约26.7百万美元 |
专营经皮冠状动脉介入治疗(「PCI」)及经皮腔内血管成形术(「PTA」)手术介入器械的全球主要医疗器械制造商业聚医疗集团控股有限公司(「业聚医疗」或「集团」;股份代号:6929),今天公布在2022年12月23日于香港联合交易所有限公司(「香港联交所」)主板上市后首份全年业绩。 more info >> |
|
業聚醫療公佈上市後首份全年業績,收入創新高達1.37億美元,經調整淨利潤升25%至約26.7百萬美元 |
專營經皮冠狀動脈介入治療(「PCI」)及經皮腔內血管成形術(「PTA」)手術介入器械的全球主要醫療器械製造商業聚醫療集團控股有限公司(「業聚醫療」或「集團」;股份代號:6929),今天公佈在2022年12月23日於香港聯合交易所有限公司(「香港聯交所」)主板上市後首份全年業績。 more info >> |
|
OrbusNeich Announces First Annual Results After Listing, Record Revenue of US$136.8 Million, Adjusted Net Profit Up 25% to US$26.7 Million |
OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures more info >> |
|
Friday, December 23, 2022 |
|
全球主要医疗器械制造商业聚医疗集团之股份于香港联交所主板挂牌上市 |
专营经皮冠状动脉介入治疗(PCI)及经皮腔内血管成形术(PTA)手术介入器械的全球主要医疗器械制造商业聚医疗集团控股有限公司(「业聚医疗」或「集团」)的股份今天于香港联合交易所有限公司(「香港联交所」)主板正式挂牌买卖,股份代号为6929。 more info >> |
|
全球主要醫療器械製造商業聚醫療集團之股份於香港聯交所主板掛牌上市 |
專營經皮冠狀動脈介入治療(PCI)及經皮腔內血管成形術(PTA)手術介入器械的全球主要醫療器械製造商業聚醫療集團控股有限公司(「業聚醫療」或「集團」)的股份今天於香港聯合交易所有限公司(「香港聯交所」)主板正式掛牌買賣,股份代號為6929。 more info >> |
|
Shares of Major Global Medical Device Manufacturer OrbusNeich Medical Group Commence Trading on the Main Board of The Stock Exchange of Hong Kong |
Shares of OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"), a major global medical device manufacturer specialized in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, today commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("HKEX"), under the stock code 6929. more info >> |
|
Tuesday, December 13, 2022 |
|
Major Global Medical Device Manufacturer OrbusNeich Medical Group Announces Details of Proposed Listing on the Main Board of HKEX |
OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"), a major global medical device manufacturer specialized in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, has today announced the details of its proposed listing on the Main Board of The Stock Exchange of Hong Kong Limited ("HKEX"). more info >> |
|
全球主要医疗器械制造商业聚医疗集团公布在香港联交所主板上市计划详情 |
专营经皮冠状动脉介入治疗(PCI)及经皮腔内血管成形术(PTA)手术介入器械的全球主要医疗器械制造商业聚医疗集团控股有限公司(「业聚医疗」或「集团」)今日公布在香港联合交易所有限公司(「香港联交所」)主板上市计划的详情。 more info >> |
|
全球主要醫療器械製造商業聚醫療集團公佈在香港聯交所主板上市計劃詳情 |
專營經皮冠狀動脈介入治療(PCI)及經皮腔內血管成形術(PTA)手術介入器械的全球主要醫療器械製造商業聚醫療集團控股有限公司(「業聚醫療」或「集團」)今日公佈在香港聯合交易所有限公司(「香港聯交所」)主板上市計劃的詳情。 more info >> |
|
|
|